IMCC vs. MTEX, NURO, GRAY, HSCS, GBS, SYRA, IBIO, CHRO, CELZ, and TENX
Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Mannatech (MTEX), NeuroMetrix (NURO), Graybug Vision (GRAY), Heart Test Laboratories (HSCS), GBS (GBS), Syra Health (SYRA), iBio (IBIO), Chromocell Therapeutics (CHRO), Creative Medical Technology (CELZ), and Tenax Therapeutics (TENX). These companies are all part of the "medical" sector.
Mannatech (NASDAQ:MTEX) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.
Mannatech has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
In the previous week, Mannatech and Mannatech both had 1 articles in the media. IM Cannabis' average media sentiment score of 0.50 beat Mannatech's score of -0.50 indicating that Mannatech is being referred to more favorably in the media.
13.0% of Mannatech shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 53.1% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Mannatech received 273 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 74.60% of users gave Mannatech an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote.
Mannatech has higher revenue and earnings than IM Cannabis. Mannatech is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.
Mannatech has a net margin of -1.70% compared to Mannatech's net margin of -16.42%. IM Cannabis' return on equity of -19.19% beat Mannatech's return on equity.
Summary
Mannatech beats IM Cannabis on 11 of the 14 factors compared between the two stocks.
Get IM Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
IM Cannabis Competitors List
Related Companies and Tools